Skip to main content
SpringerLink
Log in

CD47 checkpoint data supercharge Stanford spinout IPO

  • News
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

A News to this article was published on 01 October 2018

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 26 September 2018

    This News Analysis described ongoing trials for drugs targeting CD47. However, the article omitted mention of a clinical trial with an anti-CD47 antibody from Tioma Therapeutics, which was terminated on the death of the first patient dosed. This fatality, potentially ascribed to red cell agglutination, may have some bearing on other trials with anti-CD47 antibodies.

Author information

Authors and Affiliations

  1. Somerville, Massachusetts

    Elie Dolgin

Authors
  1. Elie Dolgin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dolgin, E. CD47 checkpoint data supercharge Stanford spinout IPO. Nat Biotechnol 36, 671–672 (2018). https://doi.org/10.1038/nbt0818-671

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0818-671

  • Springer Nature America, Inc.

Search

Navigation